X
HRTX icon

Xponance’s Heron Therapeutics HRTX Stock Holding History

Xponance’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Buy
13,735
+1,842
+15% +$2.13K ﹤0.01% 1679
2025
Q4 		$15.5K Hold
11,893
– – ﹤0.01% 1565
2025
Q3 		$15K Hold
11,893
– – ﹤0.01% 1524
2025
Q2 		$24.6K Buy
+11,893
New +$24.3K ﹤0.01% 1491

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Xponance's HRTX Position: Q1 2026 in Review

Xponance increased its Heron Therapeutics (HRTX) stake by 15% in Q1 2026, buying an estimated $2.13K and bringing the position to 13,735 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Xponance first reported a position in HRTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $24.6K in Q2 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Xponance held 13,735 shares of Heron Therapeutics worth $11K as of Q1 2026.
  • Xponance bought 1,842 Heron Therapeutics shares in Q1 2026, an estimated $2.13K.
  • Heron Therapeutics made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1679 holding.
  • Xponance first reported a position in Heron Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Xponance's Heron Therapeutics position peaked at $24.6K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.